Editorial/opinion piece
Many patients with advanced cancer will develop bone metastases and associated complications, including severe pain and debilitating skeletal-related events (SREs), which require radiotherapy, surgery or changes to antineoplastic regimens [1] [2] [3] . Fortunately, there are effective treatments to prevent or delay the onset of SREs. Several intravenous and oral bisphosphonates have been used for over a decade. More recently, denosumab (120 mg monthly, subcutaneous injection) has been added to the field of bone-targeted agents, having demonstrated superior efficacy over zoledronic acid (4 mg every 3-4 weeks, intravenous injection), the previous standard of care [4] . However, a clinical practice survey of patients with bone metastases suggests that many patients have not been receiving optimal treatment [5] .
This 2010 audit, conducted in France, Germany, Italy, Spain and the United Kingdom, was divided into two sections. In the first part, physicians completed a brief questionnaire about all patients who had bone metastases or who were being treated with bisphosphonates for cancer-related reasons. A detailed questionnaire was then completed for the next 11 consecutive patients the physicians saw who met the study criteria. Cases were weighted according to the probability of prospective inclusion in the study (i.e. based on patient consultation frequency and length of observation period).
Of the 17,193 patients included in the first part of the audit, 35% had prostate cancer, 21% of patients had breast cancer, 16% had multiple myeloma and 11% had lung cancer. The remaining patients had other solid tumors or non-Hodgkin's lymphoma. Patient characteristics were largely consistent across the five countries. Of concern, data from the brief questionnaires showed that, of the patients with bone metastases (n ¼14,871), only 53% were receiving bisphosphonates (the only bone-targeted agents available at the time of this study). One-fifth had discontinued treatment, 10% were expected to receive bisphosphonates in the future and 17% were expected never to receive bisphosphonates.
Detailed questionnaires were completed for a further 9303 patients to establish the reasons behind the clinical practice patterns. Reasons for bisphosphonate discontinuation were mainly (in 56% of cases) listed as 'end of treatment as planned'. Most individuals who stopped treatment received bisphosphonates for 2 years or less (83%) and many (36%) received treatment for 1 year or less. There was considerable variation across countries, from 14% of patients in Germany receiving bisphosphonates for 1 year or less, to 64% of patients in the UK. Assuming patients are tolerating bisphosphonates, the question remains why should physicians plan a specific treatment duration? Notably, most major guidelines do not recommend a restricted duration of therapy. There are limited data on long-term administration of these agents, but the information available suggests that the efficacy and safety profiles of bone-targeted agents are maintained over time [6] . Therefore, in the absence of a toxicity or adherence issue, there appears to be no obvious rationale to stop treatment.
Perhaps physicians are not fully aware of the risk-benefit profile of bone-targeted agents? A poor risk-benefit ratio and renal issues were key reasons for patients never receiving bisphosphonates, cited for 34% and 37% of individuals, respectively. Short life expectancy was another major reason for not treating patients (38%), despite 72% being at moderate-to-high risk of an SRE. Furthermore, over 60% of these patients were considered by their treating physician to be expected to live for more than 1 year. Considering that the mean time to an SRE is less than 2 months since diagnosis [7] , with patients experiencing events every 3-6 months thereafter [8] , patients with short life expectancies can still benefit from treatment. The chief objectives for treatment of patients with terminal cancer are palliation of symptoms and maintenance of quality of life; these are just as important when life expectancy is short. Bone-targeted agents can help to achieve these aims by preventing worsening of pain and avoiding the associated increased need for strong analgesics [9] .
Reassuringly, for the majority of patients in whom treatment with bisphosphonates was delayed, the reason cited was 'bone metastases controlled by initial anti-tumour treatment' (56%). The audit also found, however, that a significant proportion of patients had their treatment delayed owing to safety concerns (31%), which included existing renal impairment (61%), dental health issues (28%) and avoidance of renal deterioration (20%). New bone-targeted agents that are not contraindicated in renal impairment, such as denosumab, may offer alternative options for patients whom physicians are reluctant to treat with bisphosphonates owing to renal issues. While maintaining dental health is important with both bisphosphonates and denosumab, studies suggest that it may be possible to reduce the risk of osteonecrosis of the jaw by carrying out preventive dental measures prior to treatment with bone-targeted agents and by avoiding invasive dental procedures while patients are on treatment [10] [11] [12] .
The data also revealed notable differences in practice patterns across the countries. In France, Italy, Spain and the UK, patients were most likely to have multiple disseminated sites of metastases at the time of initial bone metastasis detection; however, patients in Germany were most likely to have a solitary bone metastasis. This suggests that bone metastases were more likely to be detected at an earlier stage in Germany than in other countries, meaning patients potentially received bisphosphonate treatment for longer than those in the other countries. Data from the audit on the circumstances surrounding bone metastasis detection supported this theory, with routine screening for metastases being much more common in Germany (38% of metastases were discovered this way) than in the other four countries (6-24%). Germany may offer a good example in this area as bone-targeted agents are beneficial even when initiated early in metastatic disease [1] . Thus, prompt diagnosis may result in patients experiencing fewer SREs overall.
The results of this audit suggest that the clinical management of bone metastases is at times suboptimal in these major European countries. Data from a study of a US claims database conducted by Hagiwara et al. [13] suggest that this issue is not confined to Europe. In their analysis, only 58.5% of patients with breast cancer received intravenous bisphosphonates in the first year after bone metastasis detection, and this proportion was even lower for those with prostate or lung cancer. Although it is some years since these studies were carried out, we believe that these data still have relevant implications for clinical practice. The recent introduction of denosumab may have improved access to treatment for patients with renal impairment, but other perceived barriers such as short life expectancy and short planned treatment duration are likely to persist in the clinic.
Encouragingly, the Skeletal Care Academy steering committee (composed of international experts in the field of cancer-related bone disease; oncologists, urologists, surgeons, nurses and patient advocacy groups) has put together a Patient Charter, setting out the basic requirements for standards of patient care in cancer-related bone disease [14] . This charter emphasizes the need for a multidisciplinary team who should understand the various management strategies available for patients with bone metastases. Increasing physicians' and nurses' awareness of different treatment strategies, together with improved clinical practice guidelines on optimal treatment duration and treatment of patients with short life expectancies, may help to improve patient access to effective therapies. Furthermore, prompt detection of bone metastases, as seen in Germany, may allow patients early access to bone-targeted agents, thereby delaying or avoiding debilitating bone complications and pain.
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